Drug Profile
SY 008
Alternative Names: SY-008Latest Information Update: 28 Aug 2023
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Developer Eli Lilly and Company; Yabao Pharmaceutical Group
- Class Antihyperglycaemics; Small molecules
- Mechanism of Action Sodium-glucose transporter 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Diabetes mellitus; Type 2 diabetes mellitus
Most Recent Events
- 28 Aug 2023 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus in China (PO)
- 15 Dec 2021 Yabao Pharmaceutical completes a phase I clinical trial in Type 2 diabetes mellitus in China (PO) (NCT04345120)
- 28 Apr 2021 No recent reports of development identified for phase-I development in Diabetes-mellitus(In volunteers) in China (PO)